Clarivate Acquires Bioinfogate For Undisclosed Terms To Expand Drug R&D Intelligence

  • Clarivate PLC CLVT acquired Bioinfogate, an analytics solutions provider in the life sciences and producer of the OFF-X portal. 
  • The financial terms of the transaction remain undisclosed. 
  •  The acquisition of Bioinfogate will fill a critical need for drug toxicity data and translational safety intelligence across all stages of drug R&D. 
  • With previously acquired Cortellis, OFF-X will provide critical translational safety intelligence alongside a robust drug pipeline and clinical research information.
  • Beyond Cortellis, OFF-X will strengthen other Clarivate products and services, including the Web of Science, the publisher-independent global citation database. 
  • Clarivate held $2.6 billion in cash and equivalents as of Jun. 30.
  • Price action: CLVT shares closed higher by 1.53% at $23.16 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: M&ANewsTechBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!